FDA approves new type of non-opioid pain medication
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
Fact check: Kennedy repeats false and misleading claims in confirmation hearing
In his first Senate confirmation hearing to be secretary of the Department of Health and Human Services, Robert F. Kennedy Jr ...
US FDA approves Axsome Therapeutics' migraine drug
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
Do food warning labels actually work? Answering your questions.
Readers had a lot to say about my latest column on the Food and Drug Administration’s proposed front-of-package labels. Most ...
FDA Approves New Painkiller That Shows Promise and Challenges of Opioid Alternatives
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
The FDA’s new, same-old food labels demand better obesity solutions
All things considered, it’s at least as likely to make health outcomes worse as it is to make most people healthier.
The Food Dyes And Additives That Are Banned In The United States vs. Europe, Explained By A Dietitian
Food additives have been a huge topic in the U.S. for years, but really caught fire earlier this month when the U.S. Food and ...
Cook: No need for red alert on food dyes
Kennedy has become a powerful voice advocating for the removal of artificial dyes and chemicals that he says are “poisoning” ...
FDA approves first new type of pain medication in 25 years
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.
WISH-TV on MSN4h
FDA redefines ‘healthy’ food labels to help consumers make informed choices
The FDA is overhauling food labels to redefine "'healthy," focusing on redefining terms and introducing new front-of-package ...
Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, potentially limiting patients’ ability to access it.